Is this weight loss drug stock a buy on the dip?

This company's anti-obesity candidate might succeed where others are failing.

Wave Life Sciences: WVE-007 Data Leaves Biotech Shaken And Stirred (Downgrade)

Wave Life Sciences shares plunged >50% after Phase 1 INLIGHT data for WVE-007 showed <1% placebo-adjusted weight loss at six ...

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Viscer…

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted ...
WFMZ-TV

Fat cells burn energy to make heat – making them the next frontier of weight loss therapies

(LOS ANGELES) Over the past few years, a new class of medications has transformed the treatment of obesity. Drugs like Ozempic, Wegovy and Mounjaro work primarily by reducing appetite, helping people ...